id,conversation_id,created_at,date,time,timezone,user_id,username,name,place,tweet,language,mentions,urls,photos,replies_count,retweets_count,likes_count,hashtags,cashtags,link,retweet,quote_url,video,thumbnail,near,geo,source,user_rt_id,user_rt,retweet_id,reply_to,retweet_date,translate,trans_src,trans_dest
1210696540794314757,1210696540794314757,2019-12-28 04:28:43 IST,2019-12-28,04:28:43,+0530,1370906497,maisacorp,MAISA,,$MAISA #biotech candidates for #2020_Buyout  * $ALXN Alexion  * $AMRN Amarin $BMRN BioMarin $BLUE bluebird bio * $CLVS Clovis  * $INCY Incyte * $NBIX Neurocrine Biosciences * $SGEN Seattle Genetics * $SRPT Sarepta Therapeutics $SAGE Sage Therapeutics * $VRTX Vertex  *owned,en,[],[],[],0,6,20,"['biotech', '2020_buyout']","['maisa', 'alxn', 'amrn', 'bmrn', 'blue', 'clvs', 'incy', 'nbix', 'sgen', 'srpt', 'sage', 'vrtx']",https://twitter.com/MaisaCorp/status/1210696540794314757,False,,0,,,,,,,,[],,,,
1208994300366934016,1208994300366934016,2019-12-23 11:44:37 IST,2019-12-23,11:44:37,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"#ROCHE $SRPT SAREPTA  THERAPEUTICS - TO RECEIVE UPFRONT PAYMENT OF $1.15 BLN, COMPRISING $750  MLN IN CASH AND $400 MLN IN SAREPTA STOCK, PRICED AT $158.59 PER SHARE",en,[],[],[],1,5,13,['roche'],['srpt'],https://twitter.com/_B_I_O_T_E_C_H_/status/1208994300366934016,False,,0,,,,,,,,[],,,,
1207339785985122304,1207339785985122304,2019-12-18 22:10:10 IST,2019-12-18,22:10:10,+0530,3426014292,semodough,dough,,"Baird Sarepta Therapeutics $SRPT) Competitor's $SLDB AAV9 DMD GT Falls Flat, Widening Sarepta's Lead-Based on the totality of the evidence presented to date we believe it is clear that SRP-9001 is safer and more effective vector as compared to the AAV9-based competitors.",en,[],[],[],0,6,30,[],"['srpt', 'sldb']",https://twitter.com/semodough/status/1207339785985122304,False,,0,,,,,,,,[],,,,
1205480920100175872,1205480920100175872,2019-12-13 19:03:42 IST,2019-12-13,19:03:42,+0530,1063180083769176064,msollender,Michelle Solly,,$SRPT Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan Financing   https://t.co/qP2BOLXBL8,en,[],['http://www.globenewswire.com/news-release/2019/12/13/1960416/0/en/Sarepta-Therapeutics-Announces-250-Million-of-Non-Dilutive-Senior-Secured-Loan-Financing.html'],[],1,3,8,[],['srpt'],https://twitter.com/MSollender/status/1205480920100175872,False,,0,,,,,,,,[],,,,
1205458529160769536,1205458529160769536,2019-12-13 17:34:44 IST,2019-12-13,17:34:44,+0530,818081647,analystwire,SIAnalystWire,,Sarepta Therapeutics $SRPT PT Raised to $210 at Piper Jaffray  https://t.co/ydSBxtxrYy,en,[],['http://streetinsider.com/r/16241267'],[],0,4,6,[],['srpt'],https://twitter.com/AnalystWire/status/1205458529160769536,False,,0,,,,,,,,[],,,,
1205267654635872256,1205267654635872256,2019-12-13 04:56:16 IST,2019-12-13,04:56:16,+0530,3426014292,semodough,dough,,$SRPT Sarepta Therapeutics Announces FDA Approval of VYONDYS 53‚Ñ¢ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53 | Sarepta Therapeutics  https://t.co/vXRPoYtlUx,en,[],['https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-fda-approval-vyondys-53tm'],[],1,6,16,[],['srpt'],https://twitter.com/semodough/status/1205267654635872256,False,,0,,,,,,,,[],,,,
1196819835373654016,1196819835373654016,2019-11-19 21:27:39 IST,2019-11-19,21:27:39,+0530,2301447628,tazman9tazman,Tazman,,"Sarepta Therapeutics, Inc. (SRPT) Institutional Ownership &amp; Holdings -  https://t.co/XinLum1jRs $srpt been waiting for the results Big players are updated except for one at the bottom from June to September there‚Äôs been an increase from 96.87 to99.7   https://t.co/hLMhIzHgDe",en,[],"['http://NASDAQ.com', 'https://old.nasdaq.com/symbol/srpt/institutional-holdings']",[],2,1,12,[],['srpt'],https://twitter.com/Tazman9Tazman/status/1196819835373654016,False,,0,,,,,,,,[],,,,
1196417424809218048,1196417424809218048,2019-11-18 18:48:37 IST,2019-11-18,18:48:37,+0530,14314271,sgonzalezyanes,Sebastian Gonzalez,,$Srpt Sarepta Therapeutics,tl,[],[],[],0,0,16,[],['srpt'],https://twitter.com/sgonzalezyanes/status/1196417424809218048,False,https://twitter.com/jennmcnary/status/1194235158838366208,0,,,,,,,,[],,,,
1192573739143225344,1192573739143225344,2019-11-08 04:15:11 IST,2019-11-08,04:15:11,+0530,102094857,adamfeuerstein,Adam Feuerstein,,Sarepta Therapeutics CEO playing nice with FDA over rejection of Duchenne drug  https://t.co/8ZwvYdFnjb $SRPT,en,[],['https://www.statnews.com/2019/11/07/sarepta-therapeutics-ceo-fda-duchenne-drug/'],[],4,7,14,[],['srpt'],https://twitter.com/adamfeuerstein/status/1192573739143225344,False,,0,,,,,,,,[],,,,
1187468676695355392,1187468676695355392,2019-10-25 02:09:29 IST,2019-10-25,02:09:29,+0530,223589965,gantosj,Joe,,"$SRPT Sarepta Therapeutics to Announce Third Quarter 2019 Financial Results and Recent Corporate Developments on November 7, 2019 after the market close &amp; CC  at 4:30pm ET  https://t.co/jHD97UAuGo",en,[],['https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announce-third-quarter-2019-financial'],[],0,0,14,[],['srpt'],https://twitter.com/GantosJ/status/1187468676695355392,False,,0,,,,,,,,[],,,,
1177566071542255617,1177566071542255617,2019-09-27 18:20:04 IST,2019-09-27,18:20:04,+0530,102527566,biorunup,BioRunUp,,"$SRPT Citi analyst Joel Beatty lowered his price target for Sarepta Therapeutics to $180 from $185 to reflect ""decreased conviction"" on the approvability of both Golodirsen and Casimersen ""Golodirsen is very unlikely to ever be approved""  Beatty keeps a Buy rating on Sarepta",en,[],[],[],5,1,6,[],['srpt'],https://twitter.com/BioRunUp/status/1177566071542255617,False,,0,,,,,,,,[],,,,
1176836387330568192,1176836387330568192,2019-09-25 18:00:33 IST,2019-09-25,18:00:33,+0530,41458395,tradertexmex,TexMex,,"$SRPT Sarepta Therapeutics to Announce 9-Month Functional Results from the SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy; Oct 4th 8am",en,[],[],[],0,2,8,[],['srpt'],https://twitter.com/TraderTexMex/status/1176836387330568192,False,,0,,,,,,,,[],,,,
1163911134065434627,1163911134065434627,2019-08-21 02:00:13 IST,2019-08-21,02:00:13,+0530,19717430,zbiotech,zach,,"In light of Monday‚Äôs news regarding the New Drug Application for golodirsen, PPMD has invited representatives from Sarepta Therapeutics to answer questions from the Duchenne community. Join us Wednesday, August 21 at 3pm eastern.   https://t.co/sHWrahNosQ  $SRPT",en,[],['https://cc.readytalk.com/registration/#/?meeting=w9gl7fy99tgs&campaign=4bvekxpz4to2'],[],1,4,16,[],['srpt'],https://twitter.com/zbiotech/status/1163911134065434627,False,,0,,,,,,,,[],,,,
1163569122564804614,1163569122564804614,2019-08-20 03:21:11 IST,2019-08-20,03:21:11,+0530,3426014292,semodough,dough,,$SRPT Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application | Sarepta Therapeutics  https://t.co/XI8eI0Hk1A,en,[],['https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-receives-complete-response-letter-us-food'],[],1,2,6,[],['srpt'],https://twitter.com/semodough/status/1163569122564804614,False,,0,,,,,,,,[],,,,
1163568493767397381,1163568493767397381,2019-08-20 03:18:41 IST,2019-08-20,03:18:41,+0530,41458395,tradertexmex,TexMex,,$SRPT Sarepta Therapeutics Receives Complete Response Letter from the US Food and Drug Administration for Golodirsen New Drug Application,en,[],[],[],0,11,8,[],['srpt'],https://twitter.com/TraderTexMex/status/1163568493767397381,False,,0,,,,,,,,[],,,,
1159547430293188608,1159547430293188608,2019-08-09 01:00:25 IST,2019-08-09,01:00:25,+0530,223589965,gantosj,Joe,,$SRPT Sarepta Therapeutics Comments on Erroneous Submission to US FDA Adverse Event Reporting System (FAERS)  https://t.co/DOVErj6KlY,en,[],['https://www.globenewswire.com/news-release/2019/08/08/1899510/0/en/Sarepta-Therapeutics-Comments-on-Erroneous-Submission-to-US-FDA-Adverse-Event-Reporting-System-FAERS.html'],[],2,12,17,[],['srpt'],https://twitter.com/GantosJ/status/1159547430293188608,False,,0,,,,,,,,[],,,,
1159194602626310151,1159194602626310151,2019-08-08 01:38:24 IST,2019-08-08,01:38:24,+0530,223589965,gantosj,Joe,,$SRPT Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments Q2 revenue $94.7M,en,[],[],[],0,2,12,[],['srpt'],https://twitter.com/GantosJ/status/1159194602626310151,False,,0,,,,,,,,[],,,,
1155886627748798470,1155886627748798470,2019-07-29 22:33:42 IST,2019-07-29,22:33:42,+0530,809065245876645888,stock_truth,StockTrooth,,Welcome to Twitter @AlbertBourla.  Let me be the first to introduce you to your gene therapy competition: @Sarepta Therapeutics  May the safest and most efficacious drug prevail. üß¨ü¶†  $SRPT $PFE  https://t.co/SsB3zUFkoS,en,"[{'screen_name': 'albertbourla', 'name': 'albertbourla', 'id': '1154781658933006337'}, {'screen_name': 'sarepta', 'name': 'sarepta therapeutics', 'id': '2216555822'}]",[],['https://pbs.twimg.com/media/EAqIwPKWkAACCAM.jpg'],1,1,13,[],"['srpt', 'pfe']",https://twitter.com/Stock_Truth/status/1155886627748798470,False,,1,https://pbs.twimg.com/media/EAqIwPKWkAACCAM.jpg,,,,,,,[],,,,
1150123396333785088,1150123396333785088,2019-07-14 00:52:40 IST,2019-07-14,00:52:40,+0530,401575573,dividendc2,dividendc2,,"MY TOP5 best companies bio      tec           hno                logy  1: Amgen Inc $AMGN   2: Vertex Pharmaceuticals Incorporated $VRTX  3: Illumina, Inc. $ILMN  4: Sarepta Therapeutics, Inc. $SRPT  5: Array Biopharma Inc $ARRY",en,[],[],[],2,4,10,[],"['amgn', 'vrtx', 'ilmn', 'srpt', 'arry']",https://twitter.com/dividendc2/status/1150123396333785088,False,,0,,,,,,,,[],,,,
1148467305157935104,1148467305157935104,2019-07-09 11:11:57 IST,2019-07-09,11:11:57,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,Morgan Stanley $SRPT Sarepta Therapeutics Inc: Clear DMD Gene Therapy Leader; PT to $220,en,[],[],[],1,2,14,[],['srpt'],https://twitter.com/_B_I_O_T_E_C_H_/status/1148467305157935104,False,,0,,,,,,,,[],,,,
1148308390415872006,1148308390415872006,2019-07-09 00:40:29 IST,2019-07-09,00:40:29,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"RBC research note out $SRPT ""Sarepta Therapeutics, Inc.  - Why We Believe Microdystrophin's Safety Profile Will Remain Superior, And A Key Differentiator""  anyone interested ?  sorry i dont post .. posting DD is worthless  !",en,[],[],[],1,0,7,[],['srpt'],https://twitter.com/_B_I_O_T_E_C_H_/status/1148308390415872006,False,,0,,,,,,,,[],,,,
1147951739514920960,1147951739514920960,2019-07-08 01:03:17 IST,2019-07-08,01:03:17,+0530,820529659,deanirving2,Dean Irving,,"$SRPT Aug 30, 2019 - Sept 1, 2019 National Limb Girdle Muscular Dystrophy Conference sponsored by Sarepta Therapeutics. Jerry Mendell, MD, NCH presentation Sept 1st 1 PM and Louise Rodino-Klapac, PhD, Sarepta Therapeutics presentation Sept 1st 1:25 PM  https://t.co/IS0hvUE5hz",en,[],['https://nationallimbgirdlemusculardystrophyconference.com/schedule'],[],0,6,29,[],['srpt'],https://twitter.com/DeanIrving2/status/1147951739514920960,False,,0,,,,,,,,[],,,,
1147525745314603012,1147525745314603012,2019-07-06 20:50:32 IST,2019-07-06,20:50:32,+0530,3426014292,semodough,dough,,Also interesting most of models I see $SRPT Valuation: Sarepta Therapeutics (SRPT) Discounted Cash Flow (DCF) Analysis- 1-2 billion in free cash flow 2021-2023 - thats a lot of üí∞üí∞üí∞,en,[],[],[],2,7,31,[],['srpt'],https://twitter.com/semodough/status/1147525745314603012,False,https://twitter.com/semodough/status/1112049791125651456,0,,,,,,,,[],,,,
1145172973411852288,1140843592161865733,2019-06-30 09:01:27 IST,2019-06-30,09:01:27,+0530,906328017986899968,the_chart_life,"Ian McMillan, CMT",,"$SRPT Sarepta Therapeutics ...A small failure (really, more like a deep retest) on pretty low volume. Gets right back on track and then we finally get the big move.  https://t.co/wbbe9vm1oN",en,[],[],['https://pbs.twimg.com/media/D-R4ajNW4AAOGjR.jpg'],0,4,10,[],['srpt'],https://twitter.com/the_chart_life/status/1145172973411852288,False,,1,https://pbs.twimg.com/media/D-R4ajNW4AAOGjR.jpg,,,,,,,[],,,,
1144956264960733184,1144956264960733184,2019-06-29 18:40:20 IST,2019-06-29,18:40:20,+0530,582314623,auricgoldfinqer,Auric,,$SRPT Clear Skies and Substantial Upside Potential for Sarepta Therapeutics. Credit Suisse says...Blue sky $345  https://t.co/W3SRF4Uk54,en,[],[],['https://pbs.twimg.com/media/D-OzenvWkAAN1t0.png'],1,0,16,[],['srpt'],https://twitter.com/AuricGoldFinqer/status/1144956264960733184,False,,1,https://pbs.twimg.com/media/D-OzenvWkAAN1t0.png,,,,,,,[],,,,
1144713357477535745,1144713357477535745,2019-06-29 02:35:06 IST,2019-06-29,02:35:06,+0530,3300833041,ibd_rbritt,Russ Britt,,Sarepta Therapeutics $SRPT shares rocketed Friday after Pfizer $PFE said its gene therapy test is on pause following serious side effects in two boys with Duchenne muscular dystrophy. .... IBD's Allison Gatlin @IBD_AGatlin explains. ....  https://t.co/KpPfsT1fAJ,en,"[{'screen_name': 'ibd_agatlin', 'name': 'allison gatlin', 'id': '3300865039'}]",['http://ow.ly/bm5Z50uPuVa'],[],0,3,8,[],"['srpt', 'pfe']",https://twitter.com/IBD_RBritt/status/1144713357477535745,False,,0,,,,,,,,[],,,,
1140843592161865733,1140843592161865733,2019-06-18 10:18:02 IST,2019-06-18,10:18:02,+0530,906328017986899968,the_chart_life,"Ian McMillan, CMT",,"$SRPT Sarepta Therapeutics ...""Focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases"".  Oh man.  https://t.co/vtBYnSr5Oq",en,[],[],['https://pbs.twimg.com/media/D9UXAMnX4AA6VAo.jpg'],4,1,16,[],['srpt'],https://twitter.com/the_chart_life/status/1140843592161865733,False,,1,https://pbs.twimg.com/media/D9UXAMnX4AA6VAo.jpg,,,,,,,[],,,,
1131615416453935104,1131615416453935104,2019-05-23 23:08:34 IST,2019-05-23,23:08:34,+0530,223589965,gantosj,Joe,,$SRPT Official statement following ICER report Sarepta Therapeutics Statement on ICER Draft Evidence Report for Treatments for Duchenne Muscular Dystrophy  https://t.co/9kty1qm9Hz,en,[],['http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-statement-icer-draft-evidence-report'],[],5,4,42,[],['srpt'],https://twitter.com/GantosJ/status/1131615416453935104,False,,0,,,,,,,,[],,,,
1128287539322859520,1128287539322859520,2019-05-14 18:44:46 IST,2019-05-14,18:44:46,+0530,2301447628,tazman9tazman,Tazman,,"Sarepta Therapeutics, Inc. (SRPT) Institutional Ownership &amp; Holdings -  https://t.co/XinLum1jRs $srpt from 93% to 101% not all updated yet you wonder who been stealing your shares when people  sell it‚Äôs the institutionsü§∑üèª‚Äç‚ôÇÔ∏èüòú  https://t.co/I2KzWDnsoa",en,[],"['http://NASDAQ.com', 'https://www.nasdaq.com/symbol/srpt/institutional-holdings']",[],1,0,11,[],['srpt'],https://twitter.com/Tazman9Tazman/status/1128287539322859520,False,,0,,,,,,,,[],,,,
1122164988565753857,1122164988565753857,2019-04-27 21:15:56 IST,2019-04-27,21:15:56,+0530,582314623,auricgoldfinqer,Auric,,"ASGCT meeting next week. Louise Rodino-Klapac, Sarepta Therapeutics.  Neuromuscular Targeted Therapies Wed, May 01 11:45 AM - 12:30 PM. $SRPT  https://t.co/sU2Lumoav2",en,[],[],['https://pbs.twimg.com/media/D5K6_ULX4AEoeMH.png'],1,0,7,[],['srpt'],https://twitter.com/AuricGoldFinqer/status/1122164988565753857,False,,1,https://pbs.twimg.com/media/D5K6_ULX4AEoeMH.png,,,,,,,[],,,,
1118141096104792064,1118141096104792064,2019-04-16 18:46:26 IST,2019-04-16,18:46:26,+0530,223589965,gantosj,Joe,,$SRPT Sarepta Therapeutics Inc. at the 2019 Muscular Dystrophy Association #MDA Clinical &amp; Scientific Conference Link to download a PDF for the 5 posters  https://t.co/RCsJNCun1M,en,[],['http://investorrelations.sarepta.com/events/event-details/sarepta-therapeutics-inc-2019-muscular-dystrophy-association-mda-clinical'],[],0,3,19,['mda'],['srpt'],https://twitter.com/GantosJ/status/1118141096104792064,False,,0,,,,,,,,[],,,,
1117792653158993921,1117792653158993921,2019-04-15 19:41:50 IST,2019-04-15,19:41:50,+0530,223589965,gantosj,Joe,,Paragon announces its second GMP manufacturing facility and the expansion of its strategic collaboration in manufacturing design and operation with #GeneTherapy leader Sarepta Therapeutics $SRPT   https://t.co/PMEhayuMim,en,[],['https://www.prnewswire.com/news-releases/paragon-announces-its-second-gmp-manufacturing-facility-and-the-expansion-of-its-strategic-collaboration-in-manufacturing-design-and-operation-with-gene-therapy-leader-sarepta-therapeutics-300832029.html'],[],0,3,19,['genetherapy'],['srpt'],https://twitter.com/GantosJ/status/1117792653158993921,False,,0,,,,,,,,[],,,,
1115235032451301377,1115235032451301377,2019-04-08 18:18:46 IST,2019-04-08,18:18:46,+0530,223589965,gantosj,Joe,,$SRPT Sarepta Therapeutics‚Äô Gene Therapy Limb-Girdle Muscular Dystrophy Type 2E Clinical Data has been Accepted for a Late-breaking Oral Presentation at the 2019 MDA Clinical and Scientific Conference  https://t.co/9caSfbzHmh,en,[],['http://www.globenewswire.com/news-release/2019/04/08/1799035/0/en/Sarepta-Therapeutics-Gene-Therapy-Limb-Girdle-Muscular-Dystrophy-Type-2E-Clinical-Data-has-been-Accepted-for-a-Late-breaking-Oral-Presentation-at-the-2019-MDA-Clinical-and-Scientif.html'],[],2,7,32,[],['srpt'],https://twitter.com/GantosJ/status/1115235032451301377,False,,0,,,,,,,,[],,,,
1111245340877950977,1111245340877950977,2019-03-28 18:05:09 IST,2019-03-28,18:05:09,+0530,427877977,portefeuillefun,Volker Schulz,,$SRPT.  #Sarepta Therapeutics Announces Positive Expression Results from the #Casimersen (SRP-4045) Arm of the ESSENCE Study  https://t.co/E7QkMuX2aq.,en,[],['http://www.globenewswire.com/news-release/2019/03/28/1781283/0/en/Sarepta-Therapeutics-Announces-Positive-Expression-Results-from-the-Casimersen-SRP-4045-Arm-of-the-ESSENCE-Study.html'],[],0,2,8,"['sarepta', 'casimersen']",['srpt'],https://twitter.com/portefeuillefun/status/1111245340877950977,False,,0,,,,,,,,[],,,,
1111244661459505152,1111244661459505152,2019-03-28 18:02:27 IST,2019-03-28,18:02:27,+0530,19717430,zbiotech,zach,,"$SRPT  Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study  pre-NDA mtg w/FDA to be scheduled, plan to submit mid '19",en,[],[],[],1,6,9,[],['srpt'],https://twitter.com/zbiotech/status/1111244661459505152,False,,0,,,,,,,,[],,,,
1106522987228991492,1106522987228991492,2019-03-15 17:20:13 IST,2019-03-15,17:20:13,+0530,3426014292,semodough,dough,,JP $SRPT Sarepta Therapeutics Addressing Recent FAQs; Spring Conference Call Series Monday 3/18 @ 10am EST - ALERT,en,[],[],[],1,1,17,[],['srpt'],https://twitter.com/semodough/status/1106522987228991492,False,,0,,,,,,,,[],,,,
1103095002073190401,1103095002073190401,2019-03-06 06:18:37 IST,2019-03-06,06:18:37,+0530,223589965,gantosj,Joe,,"Fast as I mentioned should be a ""Bankers bought deal"" $SRPT Sarepta Therapeutics Announces Pricing of $375.0 Million Public Offering of Common Stock  Upsize from $350M to $375M &amp; at $144/share   https://t.co/NmoA6b7514",en,[],['https://www.globenewswire.com/news-release/2019/03/06/1748532/0/en/Sarepta-Therapeutics-Announces-Pricing-of-375-0-Million-Public-Offering-of-Common-Stock.html'],[],9,9,22,[],['srpt'],https://twitter.com/GantosJ/status/1103095002073190401,False,,0,,,,,,,,[],,,,
1103041751202258944,1103041751202258944,2019-03-06 02:47:01 IST,2019-03-06,02:47:01,+0530,223589965,gantosj,Joe,,"It's another one of ""Bankers bought deal"" and will be closed very quick as the bankers has their clients waiting for this offering to add more shares!  $SRPT Sarepta Therapeutics Announces Proposed $350M Public Offering of Common Stock",en,[],[],[],2,2,16,[],['srpt'],https://twitter.com/GantosJ/status/1103041751202258944,False,,0,,,,,,,,[],,,,
1102287253643186177,1102287253643186177,2019-03-04 00:48:55 IST,2019-03-04,00:48:55,+0530,494544759,yachmod,Ja Hish,,$SRPT News Flash from the year 2030! Sarepta Therapeutics announced the sale of their Pfizer division to focus more on magnetic precision engineering proteins within cells!,en,[],[],[],2,1,27,[],['srpt'],https://twitter.com/yachmod/status/1102287253643186177,False,,0,,,,,,,,[],,,,
1101081952231309312,1101081952231309312,2019-02-28 16:59:29 IST,2019-02-28,16:59:29,+0530,1029424313164881921,behindthebid,Behind The Bid,,"Geez! 177 companies reporting earnings before the market opens üò±.  Most notable are Anheuser-Busch $BUD, HP $HPQ, Square $SQ, Monster Beverage $MNST, Sarepta Therapeutics $SRPT, Limited Brands $LB, Elastic $ESTC, Bilibili $BILI, Teladoc $TDOC, Box $BOX, Boingo Wireless $WIFI",en,[],[],[],1,3,15,[],"['bud', 'hpq', 'sq', 'mnst', 'srpt', 'lb', 'estc', 'bili', 'tdoc', 'box', 'wifi']",https://twitter.com/behindthebid/status/1101081952231309312,False,,0,,,,,,,,[],,,,
1100715527532556288,1100715527532556288,2019-02-27 16:43:26 IST,2019-02-27,16:43:26,+0530,223589965,gantosj,Joe,,"Just to beat the crowd, sign up early to $SRPT LGMD2E call  Sarepta Therapeutics Limb-Girdle Muscular Dystrophy Type 2E Data Call 02/27/19 8:00 AM EST  https://t.co/MIiV4ifMM7",en,[],['http://investorrelations.sarepta.com/events/event-details/sarepta-therapeutics-update'],[],3,4,18,[],['srpt'],https://twitter.com/GantosJ/status/1100715527532556288,False,,0,,,,,,,,[],,,,
1098335214730850304,1098335214730850304,2019-02-21 03:04:55 IST,2019-02-21,03:04:55,+0530,223589965,gantosj,Joe,,"It's about time.... $SRPT Sarepta Therapeutics to Announce LGMD Type 2E Data Results and Fourth Quarter and Full-Year 2018 Financial Results and Recent Corporate Developments on February 27, 2019  https://t.co/gn5iyJLMUi",en,[],['https://globenewswire.com/news-release/2019/02/20/1738852/0/en/Sarepta-Therapeutics-to-Announce-Limb-Girdle-Muscular-Dystrophy-Type-2E-Data-Results-and-Fourth-Quarter-and-Full-Year-2018-Financial-Results-and-Recent-Corporate-Developments-on-Fe.html'],[],0,6,30,[],['srpt'],https://twitter.com/GantosJ/status/1098335214730850304,False,,0,,,,,,,,[],,,,
1096156663172730885,1096156663172730885,2019-02-15 02:48:08 IST,2019-02-15,02:48:08,+0530,3142088601,bertrandbio,Bertrand Delsuc,,"Lysogene $LYS and Sarepta Therapeutics $SRPT Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)  https://t.co/a5E1SElsd5",en,[],['https://www.businesswire.com/news/home/20190214005824/en/Lysogene-Sarepta-Therapeutics-Announce-Dosing-Patient-AAVance#.XGXa_NxuDfQ.twitter'],[],1,2,8,[],"['lys', 'srpt']",https://twitter.com/BertrandBio/status/1096156663172730885,False,,0,,,,,,,,[],,,,
1096154834468712448,1096154834468712448,2019-02-15 02:40:52 IST,2019-02-15,02:40:52,+0530,223589965,gantosj,Joe,,"Another #GeneTherapy program MPS3A $SRPT Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)  https://t.co/nNKcZVLs5i",en,[],['https://www.globenewswire.com/news-release/2019/02/14/1725808/0/en/Lysogene-and-Sarepta-Therapeutics-Announce-Dosing-of-the-First-Patient-in-AAVance-a-Phase-2-3-Clinical-Trial-Investigating-LYS-SAF302-a-Gene-Therapy-for-the-Treatment-of-MPS-IIIA-S.html'],[],1,5,27,['genetherapy'],['srpt'],https://twitter.com/GantosJ/status/1096154834468712448,False,,0,,,,,,,,[],,,,
1096152927922720768,1096152927922720768,2019-02-15 02:33:18 IST,2019-02-15,02:33:18,+0530,427877977,portefeuillefun,Volker Schulz,,"Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)  https://t.co/K1HFq5W1Vf. $SRPT $LYS",en,[],['http://www.globenewswire.com/news-release/2019/02/14/1725808/0/en/Lysogene-and-Sarepta-Therapeutics-Announce-Dosing-of-the-First-Patient-in-AAVance-a-Phase-2-3-Clinical-Trial-Investigating-LYS-SAF302-a-Gene-Therapy-for-the-Treatment-of-MPS-IIIA-S.html'],[],1,2,6,[],"['srpt', 'lys']",https://twitter.com/portefeuillefun/status/1096152927922720768,False,,0,,,,,,,,[],,,,
1095703730668867584,1095703730668867584,2019-02-13 20:48:21 IST,2019-02-13,20:48:21,+0530,33599813,love2scuba_f,FrogFish,,"The Vanguard Group just filed a ""Statement of acquisition of beneficial ownership"", which is also known as a 13G. In the filing, it appears as though The Vanguard Group claims to own 5,865,323 shares. This represents 8.25% of Sarepta Therapeutics. $srpt  https://t.co/dafcksn4L8",en,[],['https://www.sec.gov/Archives/edgar/data/873303/000093247119006120/0000932471-19-006120-index.htm'],[],2,0,12,[],['srpt'],https://twitter.com/love2scuba_f/status/1095703730668867584,False,,0,,,,,,,,[],,,,
1094891314779435009,1094891314779435009,2019-02-11 15:00:06 IST,2019-02-11,15:00:06,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"RBC: Sarepta Therapeutics, Inc.  - $SLDB's Miss Was Good, Not Bad, for $SRPT, Making Recent #Weakness #Unfounded",en,[],[],[],1,2,15,"['weakness', 'unfounded']","['sldb', 'srpt']",https://twitter.com/_B_I_O_T_E_C_H_/status/1094891314779435009,False,,0,,,,,,,,[],,,,
1090006288677982208,1090006288677982208,2019-01-29 03:28:45 IST,2019-01-29,03:28:45,+0530,494544759,yachmod,Ja Hish,,"Ja Hish Capital Has Raised Its Eyebrows, Ears and Its Position in Sarepta Therapeutics INC $SRPT as Share Price Faded Slightly",en,[],[],[],0,0,8,[],['srpt'],https://twitter.com/yachmod/status/1090006288677982208,False,,0,,,,,,,,[],,,,
1085973284062220288,1085973284062220288,2019-01-18 00:23:01 IST,2019-01-18,00:23:01,+0530,494544759,yachmod,Ja Hish,,Ja Hish Capital Has Trimmed Its Hair and Toenails But Not Its Position in Sarepta Therapeutics INC $SRPT as Share Price Increased,en,[],[],[],0,0,13,[],['srpt'],https://twitter.com/yachmod/status/1085973284062220288,False,,0,,,,,,,,[],,,,
1085919581036720129,1085919581036720129,2019-01-17 20:49:38 IST,2019-01-17,20:49:38,+0530,494544759,yachmod,Ja Hish,,Ja Hish Capital Weighs in Sarepta Therapeutics $SRPT Awesome CEO/Great Mission; Increases PT to $852,en,[],[],[],3,0,15,[],['srpt'],https://twitter.com/yachmod/status/1085919581036720129,False,,0,,,,,,,,[],,,,
1083664874075344896,1083664874075344896,2019-01-11 15:30:14 IST,2019-01-11,15:30:14,+0530,23059499,seekingalpha,Seeking Alpha,,$SRPT - Sarepta Therapeutics: It's Time To Buy The Duchenne Muscular Dystrophy And Gene Therapy Leader  https://t.co/JHPaZge03a,en,[],['https://seekingalpha.com/article/4231077-sarepta-therapeutics-time-buy-duchenne-muscular-dystrophy-gene-therapy-leader?source=feed_f'],[],3,2,18,[],['srpt'],https://twitter.com/SeekingAlpha/status/1083664874075344896,False,,0,,,,,,,,[],,,,
1082265545775304705,1082265545775304705,2019-01-07 18:49:48 IST,2019-01-07,18:49:48,+0530,223589965,gantosj,Joe,,"$SRPT Sarepta Therapeutics Inc. at the #JPM19  J.P. Morgan Healthcare Conference today 01/7/19 10:30 AM EST Link for the webcast, early registration would help:  https://t.co/oX1zlAZfgZ",en,[],['https://jpmorgan.metameetings.net/events/healthcare19/general_signin'],[],1,1,13,['jpm19'],['srpt'],https://twitter.com/GantosJ/status/1082265545775304705,False,,0,,,,,,,,[],,,,
1081164140062928898,1081164140062928898,2019-01-04 17:53:12 IST,2019-01-04,17:53:12,+0530,842110350443053056,mattfunaro,Matt Funaro,,Sarepta Therapeutics: It's Time To Buy The Duchenne Muscular Dystrophy And Gene Therapy Leader $SRPT  https://t.co/oUaQhUhQID,en,[],['https://seekingalpha.com/article/4231077'],[],1,3,29,[],['srpt'],https://twitter.com/mattfunaro/status/1081164140062928898,False,,0,,,,,,,,[],,,,
1080456929711861760,1080456929711861760,2019-01-02 19:03:00 IST,2019-01-02,19:03:00,+0530,223589965,gantosj,Joe,,$SRPT Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy  https://t.co/dQhcdFp5Qu,en,[],['https://www.globenewswire.com/news-release/2019/01/02/1679565/0/en/Sarepta-Therapeutics-Enters-into-Long-term-Strategic-Relationship-with-Aldevron-for-GMP-grade-Plasmid-in-Support-of-Gene-Therapy-Development-and-Commercial-Manufacturing-Strategy.html'],[],2,5,19,[],['srpt'],https://twitter.com/GantosJ/status/1080456929711861760,False,,0,,,,,,,,[],,,,
1080453002274557952,1080453002274557952,2019-01-02 18:47:24 IST,2019-01-02,18:47:24,+0530,223589965,gantosj,Joe,,"$SRPT Sarepta Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference on Monday, January 7th at 10:30 a.m. ET / 7:30 a.m. PT. Following the presentation there will be a Q&amp;A session starting at 11:00 a.m. ET / 8:00 a.m. PT.  https://t.co/7bE5U018OD",en,[],['https://www.globenewswire.com/news-release/2019/01/02/1679524/0/en/Sarepta-Therapeutics-to-Present-at-the-37th-Annual-J-P-Morgan-Healthcare-Conference.html'],[],1,1,10,[],['srpt'],https://twitter.com/GantosJ/status/1080453002274557952,False,,0,,,,,,,,[],,,,
1079861473860554755,1079861473860554755,2019-01-01 03:36:52 IST,2019-01-01,03:36:52,+0530,809431127303815168,buylowsellhighh,The Patient Investor,,"$srpt I wish all the hard working &amp; great people at @Sarepta Therapeutics, the entire DMD community and my fellow Sareptians a very happy, healthy &amp; prosperous New Year! I pray that GT, as well as other therapies will be able to help all inflicted with DMD lead a better life :-)",en,"[{'screen_name': 'sarepta', 'name': 'sarepta therapeutics', 'id': '2216555822'}]",[],[],2,1,32,[],['srpt'],https://twitter.com/buylowsellhighh/status/1079861473860554755,False,,0,,,,,,,,[],,,,
1075746116602220544,1075746116602220544,2018-12-20 19:03:55 IST,2018-12-20,19:03:55,+0530,223589965,gantosj,Joe,,About time $SRPT Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53  https://t.co/loxEBoTLPc,en,[],['https://globenewswire.com/news-release/2018/12/20/1670350/0/en/Sarepta-Therapeutics-Completes-Submission-of-New-Drug-Application-Seeking-Approval-of-Golodirsen-SRP-4053-in-Patients-with-Duchenne-Muscular-Dystrophy-Amenable-to-Skipping-Exon-53.html'],[],0,3,23,[],['srpt'],https://twitter.com/GantosJ/status/1075746116602220544,False,,0,,,,,,,,[],,,,
1058361516838182913,1058361516838182913,2018-11-02 19:43:43 IST,2018-11-02,19:43:43,+0530,219819629,tjcowboyup,CowboyUp,,"Sarepta Therapeutics, Inc. $SRPT, a leader in precision genetic medicine for rare diseases, today announced that management will present at the  Credit Suisse  27th Annual Healthcare Conference on  Wednesday, November 14, 2018  at 12:55 p.m. Eastern Time",en,[],[],[],0,0,6,[],['srpt'],https://twitter.com/tjcowboyup/status/1058361516838182913,False,,0,,,,,,,,[],,,,
1047819718852337664,1047819718852337664,2018-10-04 17:34:23 IST,2018-10-04,17:34:23,+0530,3426014292,semodough,dough,,GS $SRPT Sarepta Therapeutics Inc. (SRPT): DMD gene therapy impresses at WMS; reiterate Buy PT 202,en,[],[],[],0,5,18,[],['srpt'],https://twitter.com/semodough/status/1047819718852337664,False,,0,,,,,,,,[],,,,
1046733167992999936,1046733167992999936,2018-10-01 17:36:49 IST,2018-10-01,17:36:49,+0530,59485976,psk2329,PSK2329 - JHC,,$SRPT initiated with an Overweight at Cantor Fitzgerald analyst Alethia Young started Sarepta Therapeutics with an Overweight rating and $217 price target.,en,[],[],[],2,4,7,[],['srpt'],https://twitter.com/psk2329/status/1046733167992999936,False,,0,,,,,,,,[],,,,
1045966858711683073,1045724997711548416,2018-09-29 14:51:46 IST,2018-09-29,14:51:46,+0530,3150211629,thlizrd,thlizrd,,@MareaInformativ $SRPT HC Wainwright Reaffirms Buy Rating for Sarepta Therapeutics; PT set at $267  https://t.co/XwYcXM6vcY,en,[],[],['https://pbs.twimg.com/tweet_video_thumb/DoQFTzIWkAA0dwO.jpg'],0,4,18,[],['srpt'],https://twitter.com/thlizrd/status/1045966858711683073,False,,1,https://pbs.twimg.com/tweet_video_thumb/DoQFTzIWkAA0dwO.jpg,,,,,,,"[{'screen_name': 'MareaInformativ', 'name': 'Marea Informative', 'id': '785119295927750656'}]",,,,
1038176514540531712,1038176514540531712,2018-09-08 02:55:44 IST,2018-09-08,02:55:44,+0530,471121755,pnani456,Ani Anirudhan,,$SRPT Sarepta Therapeutics CEO has a 'big ambition' for muscular dystrophy gene therapy  https://t.co/Sz4C8ltbjt,en,[],['https://cnb.cx/2Mbi8Dn'],[],0,5,14,[],['srpt'],https://twitter.com/pnani456/status/1038176514540531712,False,,0,,,,,,,,[],,,,
1036955371276001280,1036955371276001280,2018-09-04 18:03:20 IST,2018-09-04,18:03:20,+0530,223589965,gantosj,Joe,,"$SRPT Sarepta Therapeutics to Present at Two Upcoming Investor Conferences Morgan Stanley 16th Annual Global Healthcare Conference on Wednesday, September 12, 2018 at 4:15 p.m. E.T  Janney Montgomery Scott Healthcare Conference on Tuesday, September 18, 2018 at 8:15 a.m. E.T.",en,[],[],[],0,4,27,[],['srpt'],https://twitter.com/GantosJ/status/1036955371276001280,False,,0,,,,,,,,[],,,,
1027288424120762368,1027288424120762368,2018-08-09 01:50:21 IST,2018-08-09,01:50:21,+0530,168548023,bikepeddle,Adam K,,"Well Lacerta has a familiar name on it;s BoD:  Matthew Gall,  Director ""Matt is currently Vice President, Head of Business Development and Treasurer at Sarepta Therapeutics where he has played an integral role in assembling Sarepta‚Äôs gene therapy pipeline.""  $SRPT",en,[],[],[],1,0,8,[],['srpt'],https://twitter.com/Bikepeddle/status/1027288424120762368,False,,0,,,,,,,,[],,,,
1027285209950117888,1027285209950117888,2018-08-09 01:37:34 IST,2018-08-09,01:37:34,+0530,223589965,gantosj,Joe,,$SRPT beating the analysts estimate with $73.5M in Q2 Sarepta Therapeutics Announces Second Quarter 2018 Financial Results and Recent Corporate Developments Second quarter 2018 EXONDYS 51¬Æ (eteplirsen) total net revenues of $73.5 million   https://t.co/wAqLaP21WI,en,[],['https://globenewswire.com/news-release/2018/08/08/1549205/0/en/Sarepta-Therapeutics-Announces-Second-Quarter-2018-Financial-Results-and-Recent-Corporate-Developments.html'],[],0,7,20,[],['srpt'],https://twitter.com/GantosJ/status/1027285209950117888,False,,0,,,,,,,,[],,,,
1027284060912140288,1027284060912140288,2018-08-09 01:33:00 IST,2018-08-09,01:33:00,+0530,223589965,gantosj,Joe,,"$SRPT Sarepta Therapeutics Signs Long-term Strategic Investment and License Agreements with Lacerta Therapeutics, Gaining Rights to Multiple CNS-targeted Gene Therapy programs and Access to Important Gene Therapy Talent and Tools",en,[],[],[],0,5,22,[],['srpt'],https://twitter.com/GantosJ/status/1027284060912140288,False,,0,,,,,,,,[],,,,
1020285582470270978,1020285582470270978,2018-07-20 18:03:33 IST,2018-07-20,18:03:33,+0530,223589965,gantosj,Joe,,"$SRPT earnings 08/08 Sarepta Therapeutics to Announce Second Quarter 2018 Financial Results and Recent Corporate Developments on August 8, 2018  https://t.co/fhUIoqCnJc",en,[],['http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announce-second-quarter-2018-financial'],[],0,4,22,[],['srpt'],https://twitter.com/GantosJ/status/1020285582470270978,False,,0,,,,,,,,[],,,,
1009186809904058368,1009184860672364544,2018-06-20 03:00:59 IST,2018-06-20,03:00:59,+0530,1358146357,rudyhavenstein,"Rudy Havenstein, Transitory Base Effect.",,"Now replace Procter &amp; Gamble with Sarepta Therapeutics, Inc. $PG $SRPT @DowJones",en,"[{'screen_name': 'dowjones', 'name': 'dow jones', 'id': '151140821'}]",[],[],0,2,8,[],"['pg', 'srpt']",https://twitter.com/RudyHavenstein/status/1009186809904058368,False,,0,,,,,,,,[],,,,
1009094129358385154,1009094129358385154,2018-06-19 20:52:43 IST,2018-06-19,20:52:43,+0530,70498392,optionalert,Option Alert,,$SRPT Friday call buyer(s) see 700% gains after 60% jump for Sarepta Therapeutics! 6/22 105c from $7 to $52 in 3 days!  https://t.co/ffNGcqYW9Q,en,[],[],['https://pbs.twimg.com/media/DgEFwx4W0AEOiN2.jpg'],1,3,14,[],['srpt'],https://twitter.com/OptionAlert/status/1009094129358385154,False,,1,https://pbs.twimg.com/media/DgEFwx4W0AEOiN2.jpg,,,,,,,[],,,,
1009087186845732864,1009087186845732864,2018-06-19 20:25:07 IST,2018-06-19,20:25:07,+0530,458721535,inveuro,Gin√©s Parra üåê,,"#SRPT | Sarepta Therapeutics, Inc. üá∫üá∏  ‚ñ™Ô∏èAs√≠ se sube en #Wallstreet con noticias que da gusto leer  ‚ñ™Ô∏èResultados positivos de los primeros tres ni√±os administrados en fase 1 / 2a de un ensayo de microdistrofina de terapia g√©nica para tratar pacientes con distrofia muscular  https://t.co/J7uJoP4YmI",es,[],[],['https://pbs.twimg.com/media/DgD-XhYW0AA8elN.jpg'],5,3,13,"['srpt', 'wallstreet']",[],https://twitter.com/inveuro/status/1009087186845732864,False,,1,https://pbs.twimg.com/media/DgD-XhYW0AA8elN.jpg,,,,,,,[],,,,
1003616288889974786,1003616288889974786,2018-06-04 18:05:44 IST,2018-06-04,18:05:44,+0530,223589965,gantosj,Joe,,"A very wise decision! $SRPT Sarepta Therapeutics Appoints Louise Rodino-Klapac, Ph.D. to Lead Newly Created Gene Therapy Business Unit  https://t.co/lC4R7Ysmp8",en,[],['http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-appoints-louise-rodino-klapac-phd-lead'],[],0,2,12,[],['srpt'],https://twitter.com/GantosJ/status/1003616288889974786,False,,0,,,,,,,,[],,,,
999425199060627456,999425199060627456,2018-05-24 04:31:50 IST,2018-05-24,04:31:50,+0530,31546412,tradehawk,TradeHawk,,$SRPT Sarepta Therapeutics gets FDA Orphan Designation for Golodirsen for treatment of Duchenne muscular dystrophy (DMD)  https://t.co/BN2bl9tOfL,en,[],['https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=636818'],[],0,6,25,[],['srpt'],https://twitter.com/TradeHawk/status/999425199060627456,False,,0,,,,,,,,[],,,,
993461121297379328,993461121297379328,2018-05-07 17:32:43 IST,2018-05-07,17:32:43,+0530,90807052,wallstsai,$AI ‚Ñ¢Ô∏è,,$SRPT Sarepta Therapeutics price target raised to $109 from $75 at Needham,en,[],[],[],0,1,11,[],['srpt'],https://twitter.com/WallStSai/status/993461121297379328,False,,0,,,,,,,,[],,,,
976091269045858304,976091269045858304,2018-03-20 19:11:08 IST,2018-03-20,19:11:08,+0530,881305597,terriellsworth,Terri Ellsworth,,"Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program | Sarepta Therapeutics. Our #Duchenne community thanks you! $SRPT  https://t.co/EWX7SZUzmV",en,[],['http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-launch-route-79-duchenne'],[],0,2,13,['duchenne'],['srpt'],https://twitter.com/TerriEllsworth/status/976091269045858304,False,,0,,,,,,,,[],,,,
976075429755863040,976075429755863040,2018-03-20 18:08:11 IST,2018-03-20,18:08:11,+0530,223589965,gantosj,Joe,,"$SRPT Sarepta Therapeutics Announces Launch of Route 79, The Duchenne Scholarship Program  https://t.co/EBLeNI8ell",en,[],['https://globenewswire.com/news-release/2018/03/20/1442781/0/en/Sarepta-Therapeutics-Announces-Launch-of-Route-79-The-Duchenne-Scholarship-Program.html#.WrEAmktHq00.twitter'],[],0,1,11,[],['srpt'],https://twitter.com/GantosJ/status/976075429755863040,False,,0,,,,,,,,[],,,,
973317272344453120,973317272344453120,2018-03-13 03:28:15 IST,2018-03-13,03:28:15,+0530,3426014292,semodough,dough,,"JMP $SRPT reiterate our Market Outperform rating on Sarepta Therapeutics and raise our risk-adjusted, DCF-derived price target to $95 from $68 after increasing our probability of success for golodirsen to 70% from 30% and for casimersen to 40% from 10%.",en,[],[],[],0,4,18,[],['srpt'],https://twitter.com/semodough/status/973317272344453120,False,,0,,,,,,,,[],,,,
973159884886761483,973159884886761483,2018-03-12 17:02:51 IST,2018-03-12,17:02:51,+0530,223589965,gantosj,Joe,,$SRPT Sarepta Therapeutics Announces Plan to Submit NDA for Accelerated Approval of Golodirsen (SRP-4053) #GOLO in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53  https://t.co/gPk08HnMzu,en,[],['http://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-plan-submit-new-drug-application'],[],3,10,24,['golo'],['srpt'],https://twitter.com/GantosJ/status/973159884886761483,False,,0,,,,,,,,[],,,,
969552369670242304,969552369670242304,2018-03-02 18:07:52 IST,2018-03-02,18:07:52,+0530,223589965,gantosj,Joe,,Sarepta Therapeutics $SRPT PT Raised to $96 at Nomura/Instinet on 4Q Beat; 'Pipeline Registration Path &amp; DMD Gene Therapies Emerge in 2018'  https://t.co/UYF5VkUcuF via @Street_Insider,en,"[{'screen_name': 'street_insider', 'name': 'streetinsider.com', 'id': '84402174'}]",['http://www.streetinsider.com/Analyst+Comments/Sarepta+Therapeutics+%28SRPT%29+PT+Raised+to+%2496+at+NomuraInstinet+on+4Q+Beat%3B+Pipeline+Registration+Path+%26+DMD+Gene+Therapies+Emerge+in+2018/13893941.html'],[],0,6,17,[],['srpt'],https://twitter.com/GantosJ/status/969552369670242304,False,,0,,,,,,,,[],,,,
968481854767575040,968481854767575040,2018-02-27 19:14:02 IST,2018-02-27,19:14:02,+0530,223589965,gantosj,Joe,,$SRPT Sarepta Therapeutics to Present at Two Upcoming Investor Conferences  Cowen 03/12 at 12:00 pm ET Barclays 3/13 at 2:05 pm ET  https://t.co/N1nEcErny5,en,[],['https://finance.yahoo.com/news/sarepta-therapeutics-present-two-upcoming-133000210.html?soc_src=hl-viewer&soc_trk=tw'],[],1,2,13,[],['srpt'],https://twitter.com/GantosJ/status/968481854767575040,False,,0,,,,,,,,[],,,,
966291829023948800,966291829023948800,2018-02-21 18:11:39 IST,2018-02-21,18:11:39,+0530,223589965,gantosj,Joe,,Sarepta Therapeutics $SRPT Price Target Raised to $75 by JPMorgan analyst!,en,[],[],[],0,3,18,[],['srpt'],https://twitter.com/GantosJ/status/966291829023948800,False,,0,,,,,,,,[],,,,
956630079035015170,956630079035015170,2018-01-26 02:19:18 IST,2018-01-26,02:19:18,+0530,120949245,phatoftheland10,JO-BU,,"One patient in a study‚Äîone of two that Sarepta Therapeutics $SRPT is backing at Nationwide-hasn‚Äôt had any side effects related to the gene therapy. ‚ÄúAs far as I can see, we have a very safe product,‚Äù Mendell said üöÄüöÄüöÄüöÄ https://t.co/6gid9H3h5q",en,[],['https://www.xconomy.com/boston/2018/01/25/solid-delays-ipo-discloses-duchenne-problems-raises-rivals-hackles/?single_page=true'],[],0,1,14,[],['srpt'],https://twitter.com/phatoftheland10/status/956630079035015170,False,,0,,,,,,,,[],,,,
955446365957558274,955446365957558274,2018-01-22 19:55:39 IST,2018-01-22,19:55:39,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"RBC $SRPT Sarepta Therapeutics, Inc.  - Updating Model for Recent Guidance; Assuming Coverage at Outperform and #Raising PT to $80",en,[],[],[],0,2,8,['raising'],['srpt'],https://twitter.com/_B_I_O_T_E_C_H_/status/955446365957558274,False,,0,,,,,,,,[],,,,
950355458778263554,950355458778263554,2018-01-08 18:46:12 IST,2018-01-08,18:46:12,+0530,223589965,gantosj,Joe,,$SRPT Sarepta Therapeutics at 36th Annual J.P. Morgan Healthcare Conference  #JPM18  Presentation at 1:30 PM ET / 10:30 PT San-Fransisco... Link for the webcast   https://t.co/NocPC3m5Mr,en,[],['https://jpmorgan.metameetings.net/events/healthcare18/sessions/13499-sarepta-therapeutics-inc/webcast'],[],0,3,10,['jpm18'],['srpt'],https://twitter.com/GantosJ/status/950355458778263554,False,,0,,,,,,,,[],,,,
946011972457263105,946011972457263105,2017-12-27 19:06:44 IST,2017-12-27,19:06:44,+0530,223589965,gantosj,Joe,,"What we mentioned yesterday, now it's official by $SRPT  Sarepta Therapeutics Announces Publication of Long-Term Pulmonary Function of Eteplirsen-Treated ...  https://t.co/1h6a9rKAee",en,[],['https://finance.yahoo.com/news/sarepta-therapeutics-announces-publication-long-133000841.html?soc_src=social-sh&soc_trk=tw'],[],0,3,16,[],['srpt'],https://twitter.com/GantosJ/status/946011972457263105,False,,0,,,,,,,,[],,,,
938089903765803008,938089903765803008,2017-12-05 22:27:16 IST,2017-12-05,22:27:16,+0530,531525580,3iron78,a e  caffey,,"$SRPT Sarepta Therapeutics Elects Biopharmaceutical Veteran, Michael W. Bonney, to its Board of Directors. Was CEO of Cubist Pharmaceuticals. Cubist got bought out for a premium. Picture taking shape.....",en,[],[],[],2,1,10,[],['srpt'],https://twitter.com/3iron78/status/938089903765803008,False,,0,,,,,,,,[],,,,
928008494757838849,928008494757838849,2017-11-08 02:47:21 IST,2017-11-08,02:47:21,+0530,884391852119642112,trading_mz,Mz Trading,,SAREPTA THERAPEUTICS INC - ‚ÄçCHIEF EXECUTIVE OFFICER INDICATES INTEREST IN PURCHASING $2 MLN OF SHARES OF SAREPTA'S COMMON STOCK‚Äã $SRPT $IBB,en,[],[],[],2,6,12,[],"['srpt', 'ibb']",https://twitter.com/trading_mz/status/928008494757838849,False,,0,,,,,,,,[],,,,
927891079076171776,927891079076171776,2017-11-07 19:00:47 IST,2017-11-07,19:00:47,+0530,884391852119642112,trading_mz,Mz Trading,,"$SRPT SAREPTA THERAPEUTICS ANNOUNCES FDA CLEARANCE OF IND FOR THE COMPANY‚ÄôS PPMO EXON 51 CANDIDATE, SRP-5051",en,[],[],[],0,4,10,[],['srpt'],https://twitter.com/trading_mz/status/927891079076171776,False,,0,,,,,,,,[],,,,
910528100781322241,910528100781322241,2017-09-20 21:06:30 IST,2017-09-20,21:06:30,+0530,23009778,jonmoulton,Jon D. Moulton,,#Morpholino-based influenza drug from Sarepta Therapeutics $SRPT passes phase 1 clinical safety testing in humans:  https://t.co/HBs2uDcnmz,en,[],['http://www.sandiegouniontribune.com/business/biotech/sd-me-flu-drug-20170919-story.html'],[],3,3,18,['morpholino'],['srpt'],https://twitter.com/jonmoulton/status/910528100781322241,False,,0,,,,,,,,[],,,,
908559191786192897,908559191786192897,2017-09-15 10:42:46 IST,2017-09-15,10:42:46,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,"RBC $SRPT Sarepta Therapeutics (SRPT, Eckler) ‚Äì Outperform, $64 target ÔÇß The EXONDYS 51 launch is humming on (cont)  https://t.co/Ijy6bxjtsh",en,[],['http://tl.gd/n_1sq6f0m'],[],0,7,14,[],['srpt'],https://twitter.com/_B_I_O_T_E_C_H_/status/908559191786192897,False,,0,,,,,,,,[],,,,
900699758448312321,900699758448312321,2017-08-24 18:12:11 IST,2017-08-24,18:12:11,+0530,223589965,gantosj,Joe,,$SRPT Sarepta Therapeutics to Present at Three Upcoming Investor Conferences  https://t.co/JqD3R7pAJ2  https://t.co/mlgPAAbsif,en,[],['https://finance.yahoo.com/news/sarepta-therapeutics-present-three-upcoming-123000308.html?soc_src=social-sh&soc_trk=tw'],['https://pbs.twimg.com/media/DH_tpnyW0AQG3Tn.jpg'],2,4,16,[],['srpt'],https://twitter.com/GantosJ/status/900699758448312321,False,,1,https://pbs.twimg.com/media/DH_tpnyW0AQG3Tn.jpg,,,,,,,[],,,,
879683286565519360,879683286565519360,2017-06-27 18:20:13 IST,2017-06-27,18:20:13,+0530,223589965,gantosj,Joe,,"$SRPT Sarepta Therapeutics Announces Grand Opening of its Research &amp; Manufacturing Center at Andover, Massachusetts  https://t.co/iLXwrKr2ke  https://t.co/fCZigTEzeq",en,[],['https://globenewswire.com/news-release/2017/06/27/1029506/0/en/Sarepta-Therapeutics-Announces-Grand-Opening-of-its-Research-and-Manufacturing-Center-at-Andover.html#.WVJTsEQMVSg.twitter'],['https://pbs.twimg.com/media/DDVDAVJWsAANY-R.jpg'],1,4,21,[],['srpt'],https://twitter.com/GantosJ/status/879683286565519360,False,,1,https://pbs.twimg.com/media/DDVDAVJWsAANY-R.jpg,,,,,,,[],,,,
865273877781372928,865273877781372928,2017-05-19 00:02:23 IST,2017-05-19,00:02:23,+0530,1080306914,mattegancnn,Matt Egan,,#Biotech stock Sarepta Therapeutics pops 4% as hedge fund manager Jason Karp predicts 200%+ upside at #SALT2017. $SRPT,en,[],[],[],0,4,9,"['biotech', 'salt2017']",['srpt'],https://twitter.com/MattEganCNN/status/865273877781372928,False,,0,,,,,,,,[],,,,
858297527736684548,858297527736684548,2017-04-29 18:00:51 IST,2017-04-29,18:00:51,+0530,582314623,auricgoldfinqer,Auric,,Heres Why Sarepta Therapeutics May Be The Rarest Of Finds: A Value Biotech Stock $SRPT  https://t.co/tJ6RT54jDG via @benzinga,en,"[{'screen_name': 'benzinga', 'name': 'benzinga', 'id': '44060322'}]",['http://benzinga.com/z/9368361'],[],2,3,11,[],['srpt'],https://twitter.com/AuricGoldFinqer/status/858297527736684548,False,,0,,,,,,,,[],,,,
836922989102911488,836922989102911488,2017-03-01 18:26:04 IST,2017-03-01,18:26:04,+0530,2922234899,gupta_calling,vnmaster gupta,,$SRPT Baird Reiterates Outperform Rating and $102 PT on Sarepta Therapeutics (SRPT); Mgmt Upbeat on Exondys 51 Launch  https://t.co/Fc35ny9Ayh,en,[],[],['https://pbs.twimg.com/media/C51ZBJoVMAAHNwj.jpg'],1,4,10,[],['srpt'],https://twitter.com/Gupta_Calling/status/836922989102911488,False,,1,https://pbs.twimg.com/media/C51ZBJoVMAAHNwj.jpg,,,,,,,[],,,,
821571531033772032,821571531033772032,2017-01-18 09:44:51 IST,2017-01-18,09:44:51,+0530,3506180177,bs2537,"BSharma MD, MBA",,$SRPT: Sarepta Therapeutics (NASDAQ: SRPT: Our Next Investment (with proprietary DCF valuation).    https://t.co/7462PfJuLo,en,[],['http://seekingalpha.com/research/6496881-bhavneesh-sharma-mba/4950587-sarepta-therapeutics-nasdaq-srpt-next-investment'],[],0,0,6,[],['srpt'],https://twitter.com/bs2537/status/821571531033772032,False,,0,,,,,,,,[],,,,
781464048332406784,781464048332406784,2016-09-29 17:32:02 IST,2016-09-29,17:32:02,+0530,545618159,wrigleytom,Tom Wrigley,,$SRPT Catabasis Pharmaceuticals And Sarepta Therapeutics Announce A Joint Research Collaboration In Duchenne Muscular Dystrophy -Dow Jones,en,[],[],[],0,5,6,[],['srpt'],https://twitter.com/WrigleyTom/status/781464048332406784,False,,0,,,,,,,,[],,,,
781030151207415808,781030151207415808,2016-09-28 12:47:53 IST,2016-09-28,12:47:53,+0530,4859660471,_b_i_o_t_e_c_h_,üÖ±üÖ∏üÖæüÜÉüÖ¥üÖ≤üÖ∑,,JMP $SRPT believe the Street is underestimating the price of Exondys 51; PT to $90 from $60 on Sarepta Therapeutics  https://t.co/e4zZm4N0wC,en,[],[],"['https://pbs.twimg.com/media/CtbGuW2WcAA1StQ.jpg', 'https://pbs.twimg.com/media/CtbGva9XEAAL3Oo.jpg', 'https://pbs.twimg.com/media/CtbGwaMWIAAITuq.jpg', 'https://pbs.twimg.com/media/CtbGxbHXEAALKDo.jpg']",0,12,26,[],['srpt'],https://twitter.com/_B_I_O_T_E_C_H_/status/781030151207415808,False,,1,https://pbs.twimg.com/media/CtbGuW2WcAA1StQ.jpg,,,,,,,[],,,,
778672756300722176,778672756300722176,2016-09-22 00:40:26 IST,2016-09-22,00:40:26,+0530,52191442,cmcsherry5,Christine McSherry,,"Thank you to Dr. Ed Kaye and Sarepta Therapeutics. Ed, a former colleague Your dedication to our community is unprecedented. $SRPT",en,[],[],[],0,0,22,[],['srpt'],https://twitter.com/CMcSherry5/status/778672756300722176,False,,0,,,,,,,,[],,,,
777895051808477188,777895051808477188,2016-09-19 21:10:07 IST,2016-09-19,21:10:07,+0530,14886375,stocktwits,Stocktwits,,And here's what short interest for Sarepta Therapeutics looks like üò≥:  https://t.co/Z6eqvkqJlz  $SRPT,en,[],['http://stocktwits.com/jackdamn/message/62891915?utm_medium=community-twitter&utm_source=t.co&utm_campaign=outboundteam'],[],1,6,11,[],['srpt'],https://twitter.com/Stocktwits/status/777895051808477188,False,,0,,,,,,,,[],,,,
740639961582600192,740639961582600192,2016-06-09 01:51:41 IST,2016-06-09,01:51:41,+0530,545618159,wrigleytom,Tom Wrigley,,$SRPT  Sarepta Therapeutics Announces Proposed Offering    https://t.co/LIyZy12NYc  https://t.co/ZiGgSn7dI1,en,[],['http://finance.yahoo.com/news/sarepta-therapeutics-announces-proposed-offering-201900782.html?soc_src=mediacontentstory&soc_trk=tw'],['https://pbs.twimg.com/media/CkdIHmAUUAAPdiw.jpg'],0,6,10,[],['srpt'],https://twitter.com/WrigleyTom/status/740639961582600192,False,,1,https://pbs.twimg.com/media/CkdIHmAUUAAPdiw.jpg,,,,,,,[],,,,
735425814255173636,735425814255173636,2016-05-25 16:32:32 IST,2016-05-25,16:32:32,+0530,545618159,wrigleytom,Tom Wrigley,,$SRPT +$5 pre.. Sarepta Therapeutics Announces FDA Will Not Complete The Review Of The Eteplirsen New Drug Application By The PDUFA Date -DJ,en,[],[],[],0,4,7,[],['srpt'],https://twitter.com/WrigleyTom/status/735425814255173636,False,,0,,,,,,,,[],,,,
723491768210100224,723491768210100224,2016-04-22 18:10:54 IST,2016-04-22,18:10:54,+0530,15281391,thestreet,TheStreet,,Biotech stock mailbag: Is there a future for Sarepta Therapeutics? $SRPT  https://t.co/GTG77zMRFB  https://t.co/DCYkGzV7Od,en,[],['http://dlvr.it/L6zLqt'],['https://pbs.twimg.com/media/Cgpb7gdU0AALU9m.jpg'],2,12,14,[],['srpt'],https://twitter.com/TheStreet/status/723491768210100224,False,,1,https://pbs.twimg.com/media/Cgpb7gdU0AALU9m.jpg,,,,,,,[],,,,
677822645186990080,677822645186990080,2015-12-18 17:38:06 IST,2015-12-18,17:38:06,+0530,223589965,gantosj,Joe,,And now the official PR from $SRPT Sarepta Therapeutics Announces FDA AdCom Meeting to Review Eteplirsen  https://t.co/tO35PT0DTa,en,[],['http://finance.yahoo.com/news/sarepta-therapeutics-announces-fda-advisory-120400188.html'],[],0,3,7,[],['srpt'],https://twitter.com/GantosJ/status/677822645186990080,False,,0,,,,,,,,[],,,,
636287936841953280,636287936841953280,2015-08-26 02:54:00 IST,2015-08-26,02:54:00,+0530,14031032,adamsinger,Adam Singer,,Sarepta Therapeutics Announces FDA Has Filed Eteplirsen NDA:  http://t.co/3xK1F4o6YA $SRPT #itshappening #racetoyes,en,[],['http://finance.yahoo.com/news/sarepta-therapeutics-announces-fda-filed-211700263.html'],[],0,10,14,"['itshappening', 'racetoyes']",['srpt'],https://twitter.com/AdamSinger/status/636287936841953280,False,,0,,,,,,,,[],,,,
615475688796131328,615475688796131328,2015-06-29 16:33:33 IST,2015-06-29,16:33:33,+0530,84402174,street_insider,Streetinsider.com,,Sarepta Therapeutics $SRPT Completes NDA Submission for Eteplirsen  http://t.co/VA70Dwpy8a,en,[],['http://stks.co/i2ffw'],[],0,4,2,[],['srpt'],https://twitter.com/Street_Insider/status/615475688796131328,False,,0,,,,,,,,[],,,,
601122180001308672,601121282592223234,2015-05-21 01:57:50 IST,2015-05-21,01:57:50,+0530,14886375,stocktwits,Stocktwits,,"First up, Sarepta Therapeutics. This stock was up 60% today alone. Here's why -&gt;  http://t.co/yDzk7hxPiD $SRPT  http://t.co/pfdd22GomB",en,[],['http://stks.co/t26wH'],['https://pbs.twimg.com/media/CFedb_uW8AEyFAJ.png'],2,6,12,[],['srpt'],https://twitter.com/Stocktwits/status/601122180001308672,False,,1,https://pbs.twimg.com/media/CFedb_uW8AEyFAJ.png,,,,,,,[],,,,
593120033016061952,593120033016061952,2015-04-29 00:00:10 IST,2015-04-29,00:00:10,+0530,15752608,bosbizdon,Don Seiffert,,"Exclusive: Q&amp;A with Chris Garabedian, former CEO of Sarepta Therapeutics $SRPT  http://t.co/5jJk27zMXT",en,[],['http://bit.ly/1zkNPD1'],[],1,10,14,[],['srpt'],https://twitter.com/BosBizDon/status/593120033016061952,False,,0,,,,,,,,[],,,,
494957312050987008,494957312050987008,2014-08-01 02:56:33 IST,2014-08-01,02:56:33,+0530,102094857,adamfeuerstein,Adam Feuerstein,,"Only $SRPT PR I‚Äôm interested in reading starts like this: ‚ÄúSarepta Therapeutics announces eteplirsen has been filed with the FDA‚Ä¶""",en,[],[],[],3,6,13,[],['srpt'],https://twitter.com/adamfeuerstein/status/494957312050987008,False,,0,,,,,,,,[],,,,
492470546987515905,492470546987515905,2014-07-25 06:15:02 IST,2014-07-25,06:15:02,+0530,632341632,andybiotech,Andy Biotech,,"$SRPT-&gt; @joewalkerWSJ: Chief Scientist Is Out at Sarepta Therapeutics, Escorted Out of Building by Security - Sources  http://t.co/KJvDaMZ2RT",en,"[{'screen_name': 'joewalkerwsj', 'name': 'joseph walker', 'id': '16248719'}]",['http://online.wsj.com/articles/chief-scientist-is-out-at-sarepta-therapeutics-1406244315'],[],4,10,11,[],['srpt'],https://twitter.com/AndyBiotech/status/492470546987515905,False,,0,,,,,,,,[],,,,
458198059256524801,458198059256524801,2014-04-21 16:28:24 IST,2014-04-21,16:28:24,+0530,274233761,bradloncar,Brad Loncar,,Sarepta Therapeutics Announces Plans to Submit New Drug Application to FDA for Eteplirsen for the...  http://t.co/IIUafAWo0u $SRPT,en,[],['http://finance.yahoo.com/news/sarepta-therapeutics-announces-plans-submit-105500879.html?soc_src=mediacontentstory'],[],1,7,7,[],['srpt'],https://twitter.com/bradloncar/status/458198059256524801,False,,0,,,,,,,,[],,,,
